% | $
Quotes you view appear here for quick access.

3M Company Message Board

  • jockobano jockobano Aug 6, 2013 8:29 AM Flag

    3M and ADMP deal as per SEC Edgar

    Looks like ADMP is one to buy here under a buck. Buy it while it's cheap.
    Adamis Pharmaceuticals Signs Agreement to Acquire Dry Powder Inhaler Technology from 3M Co

    Tuesday, August 6, 9:30am ET

    San Diego, California – August 6, 2013 – Adamis Pharmaceuticals Corporation (OTCQB: ADMP) announced today that it has entered into an agreement to exclusively license and, with additional payment, fully acquire 3M Company’s (NYSE:MMM) Taper Dry Powder Inhaler (DPI) technology under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). As a part of the agreement, Adamis will obtain worldwide rights to use this platform technology in all indications in the dry powder inhalation field. The unique design uses proprietary 3M technology to store active pharmaceutical ingredient (API) on a microstructured carrier tape. 3M will supply the drug delivery tape for the platform to Adamis under a separate supply agreement. 3M Drug Delivery Systems is a pioneer in the area of novel inhalation drug delivery technology and has more than 50 years of experience and proven success in the field.

    In its current stage of development, 3M Taper Dry Powder Inhaler combines patient-friendly design and active aerosolization to provide effective delivery of drug in a multi-dose DPI. Additional advantages of the current technology include:

    · Can be used with single or combination drugs;
    · Virtually eliminates need for complex powder treatments or lactose in most formulations;
    · Holds up to 120 doses in convenient pocket sized design;
    · API dose range up to 1 milligram;
    · Protects against moisture ingress;
    · Utilizes patented 3M breath actuated technology and has simple open, inhale, close functionality;
    · Integrates dose counter to ensure patients know how many doses remain.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Thanks for the heads up. ADMP looks like it has some great stuff coming, and a generic Advair will be huge!

    • part 2
      The Taper DPI inhaler was being developed by 3M Drug Delivery Systems to compete with other dry powder inhalers such as GlaxoSmithKline’s (GSK) Advair Diskus®. According to IMS Health data, the global asthma and COPD prescription market is more than $34 billion and is averaging 7% growth per year. According to IMS, annual sales of the Advair Diskus® are approximately $5 billion in the United States and $8 billion globally for the indications of asthma and COPD. Upon completion of development and clinical activities required to obtain required regulatory approval, Adamis will seek to compete for a share of the Advair market with a branded generic version utilizing 3M’s Taper DPI technology.

      Current data indicates this platform technology has the potential to be compatible with a wide range of formulations; Adamis intends to pursue a number of other important drug candidates, which if successfully developed, could substantially increase the potential value of this transaction to Adamis and its shareholders.

163.50+0.91(+0.56%)Mar 27 4:03 PMEDT